Gossypetin Derivatives are also Putative Inhibitors of SARS-COV 2: Results of a Computational Study
Published: 1 October 2020
Journal of Biomedical Research & Environmental Sciences , Volume 1, pp 201-212; doi:10.37871/jbres1144
Abstract: SARS-CoV-2 is the third most highly virulent human coronavirus of the 21st century. It is linked with fatal respiratory illness. Currently, there are still no effective treatments of Covid-19. Among many drugs evaluated, few have proven conclusive clinical efficacy. Furthermore, the spread of the disease mandates that ideal medications against Covid-19 be cheap and available worldwide. Therefore, there is a rationale to evaluate whether treatments of natural origin from aromatic and medicinal plants have the ability to prevent and/or treat COVID-19. We evaluated in this study the inhibition of COVID-19 protease by natural plants compounds such as Gossypetin-3'-O-glucoside (G3'G). G3'G has been isolated from the petals of Talipariti elatum Sw. found almost exclusively in Martinique. It has no crystallography or modelisation studies. Antifungal and antioxidant properties are already published. We study its binding affinity so potential inhibition capability against SARS-CoV2 3CLpro mean protease as compared to other previously tested natural or pharmacological molecules by molecular docking. We propose Gossypetin derivatives as good tropical natural compounds candidate that should be further investigated to prevent or treat COVID19.
Keywords: Efficacy / protease / treatments / SARs / compounds / COVID / G3'G / Gossypetin derivatives
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Click here to see the statistics on "Journal of Biomedical Research & Environmental Sciences" .